Analysis of Revascularisation in Ischemic Stroke With EmboTrap

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-11-30

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A.R.I.S.E. is a post approval observational study using standard care. The purpose of this study is to collect information about the ability of the EmboTrap device to remove blood clots from the brain, and the associated performance characteristics and clinical outcomes. No formal hypothesis testing is needed as no comparisons are planned within the study. Instead, estimates of each population parameter of interest for all primary and secondary endpoints will be provided using appropriate confidence intervals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Revascularization in Ischemic Stroke With EmboTrap

NCT02488915

Stroke Ischemia

COMPLETED NA

First-pass Recanalization With EmboTrap II in Acute Ischemic Stroke (FREE-AIS)

NCT04310306

Acute Ischemic Stroke Due to Intracranial Large Artery Occlusion

UNKNOWN

Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke (REVISE-1)

NCT03210051

Acute Stroke

COMPLETED PHASE1

Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)

NCT01088672

Ischemic Stroke

COMPLETED PHASE4

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

NCT03601702

Acute Ischemic Stroke

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EmboTrap® Revascularization Device

The EmboTrap® Revascularization Device is the investigational device

EmboTrap® Revascularization Device

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EmboTrap® Revascularization Device

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EmboTrap

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient or the patient's legally authorized representative has signed and dated an Informed Consent Form.
* Aged between 18 years and 80 years (inclusive).
* A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
* NIHSS score ≥8 and ≤25.
* Pre-ictal mRS score of 0 or 1.
* Angiographic confirmation of an occlusion of an ICA (including T and L occlusions), M1 or M2, MCA, or BA with TICI flow of 0-1.
* Confirmation by the interventionalist, after screening CT or MRI, that the treatment site can be accessed with the Neuravi device.
* The interventionalist estimates that at least one deployment of the Neuravi device can be completed within 5 hours from the onset of symptoms, or if time of onset of symptoms is unknown or \> 5 hours, patients can be included using imaging with the following criteria:

1. MRI criterion: ASPECTS 8 to 10, or,volume of diffusion restriction ≤30 mL and mismatch between perfusion reduction and diffusion restriction present.
2. CT criterion: ASPECTS 8 to 10 on baseline CT or CTA-source images, or, volume of significantly lowered CBV ≤30 mL and mismatch between perfusion reduction and low CBV present.

Exclusion Criteria

* Life expectancy of less than 6 months.
* Females who are pregnant or lactating.
* History of severe allergy to contrast medium.
* Has suffered a stroke in the past three months.
* The patient presents with an NIHSS score \<8 or \>25 or is physician assessed as being in a clinically relevant uninterrupted coma.
* Use of warfarin anticoagulation with International Normalized Ratio (INR) \> 3.0.
* Platelet count \< 50,000.
* Glucose \< 50 mg/dL.
* Heparin use in previous 24 hours with PTT or ACT \> 2X normal.
* Any known hemorrhagic or coagulation deficiency.
* Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
* For basilar artery occlusion, extended early ischemic changes as confirmed by pc-ASPECTS ≤ 7 on baseline CT or CTA-source images, or extensive DWI lesions in the midbrain or pons regions on pre-treatment MRI.
* Baseline CT or MRI showing mass effect or intracranial tumor (except small meningioma).
* Excessive arterial tortuosity that precludes the study device from reaching the target vessel.
* A proximal stenosis or complete occlusion that cannot, as judged by the responsible interventionalist, be treated safely or which prevents access to the occluded vessel with the Neuravi device.
* Evidence of active infection.
* Known cancer with metastases
* Current use of cocaine or other vasoactive substance.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No